Can I Take Glycine with Alprostadil (Caverject/MUSE)?

What Is Alprostadil and How Does It Work?

Alprostadil is synthetic prostaglandin E1 (PGE1) approved by the FDA for the treatment of erectile dysfunction that does not respond adequately to oral phosphodiesterase-5 inhibitors. It is delivered either by intracavernosal injection under the brand name Caverject (doses ranging from 10 to 40 mcg) or as an intraurethral pellet under the brand name MUSE (125 to 1,000 mcg). FDA labeling confirms that alprostadil acts directly on prostanoid EP2 and EP3 receptors in penile smooth muscle, triggering cyclic AMP elevation, smooth-muscle relaxation, and arterial inflow. [1]

Pharmacokinetics: Why Local Delivery Matters

Because alprostadil is injected or absorbed locally in urethral tissue, systemic plasma concentrations remain low. A pharmacokinetic study showed that after a 20-mcg intracavernosal dose, peripheral venous PGE1 levels peaked at roughly 1.5 pg/mL, barely above baseline, and returned to baseline within 60 minutes. [2] This short systemic exposure window is central to understanding why oral supplement interactions are generally limited.

Known Cardiovascular Side Effects

Hypotension is the most clinically significant systemic effect. The Caverject prescribing information reports symptomatic hypotension in approximately 3% of patients at therapeutic doses. [1] Men with pre-existing hypotension, autonomic neuropathy, or cardiovascular disease face a higher baseline risk. Any co-administered substance that also lowers blood pressure warrants consideration.

What Is Glycine and Why Do Men Take It?

Glycine is the smallest amino acid. It serves three roles in human physiology: structural precursor to collagen (roughly one-third of collagen's amino acid content is glycine), inhibitory neurotransmitter in the brainstem and spinal cord, and a conditionally gluconeogenic substrate. Men commonly take glycine supplements for sleep quality, joint support, or as part of a collagen peptide powder. Doses in clinical studies range from 3 g to 15 g per day. [3]

Sleep Research

The most-cited human trial of glycine for sleep used 3 g taken 30 minutes before bed. That 2012 randomized crossover study in Frontiers in Neurology (N=11) found subjective sleep quality improved, morning fatigue scores dropped, and core body temperature fell modestly overnight, consistent with glycine's known thermoregulatory effects. [3] Men using alprostadil typically take it on-demand rather than nightly, so overlap with a nightly glycine dose is plausible.

Glycemic Effects

Glycine has a mild but real effect on glucose metabolism. A 2009 paper in Metabolism (N=74 type-2 diabetics) found that 5 g of glycine taken with a glucose load increased glucagon-like peptide-1 (GLP-1) secretion and lowered post-load glucose by approximately 10 mg/dL compared with placebo. [4] Men with diabetic ED who use alprostadil are the subgroup most likely to notice this effect.

Collagen and Vascular Tissue

Glycine contributes to vascular extracellular matrix integrity. Animal data suggest glycine supplementation may protect endothelial function, though direct human vascular trials are limited in scope. A 2016 review in Oxidative Medicine and Cellular Longevity summarized glycine's anti-inflammatory and cytoprotective effects in vascular beds without reporting adverse hemodynamic consequences. [5]

The Interaction Profile: Pharmacokinetic vs. Pharmacodynamic

Understanding whether an interaction is pharmacokinetic (one substance changes how the other is absorbed, distributed, metabolized, or excreted) or pharmacodynamic (both act on overlapping physiological endpoints) shapes the clinical recommendation.

No Pharmacokinetic Interaction Identified

Alprostadil is metabolized in the lung and by local penile tissue enzymes (15-hydroxy-prostaglandin dehydrogenase and prostaglandin 9-ketoreductase), not by hepatic CYP450 enzymes. [1] Glycine is transported and catabolized via distinct glycine cleavage enzyme systems, primarily in the liver and kidney. The two substances share no metabolic pathway, no plasma protein binding competition, and no transporter overlap that has been documented in the primary literature or in the NIH Office of Dietary Supplements interaction database. Neither the FDA label for Caverject nor the MUSE label lists glycine among interacting substances. [1]

Pharmacodynamic Concern 1: Vasodilation and Blood Pressure

This is the only pharmacodynamic overlap that deserves genuine clinical attention. Glycine activates strychnine-sensitive glycine receptors in vascular smooth muscle, and some animal perfusion data suggest modest vasodilatory effects. A 2000 study in Cardiovascular Research demonstrated that glycine infusion reduced mean arterial pressure in a rat model by approximately 10 mmHg through a central inhibitory mechanism. [6] In healthy humans, the blood pressure effect of oral glycine appears small and transient, but the data are thin.

Alprostadil already carries a 3% symptomatic hypotension rate at standard doses. [1] Stacking a vasodilatory supplement on top of an intrinsically vasodilatory drug is not dangerous in most men, but it could push a borderline case into symptomatic lightheadedness or syncope. The risk is highest in the 30 to 60 minutes after alprostadil administration, which coincides with peak local effect.

Pharmacodynamic Concern 2: Glycemic Axis

Erectile dysfunction and type-2 diabetes are closely linked. A 2020 meta-analysis in The Journal of Sexual Medicine found that approximately 52% of men with type-2 diabetes experience ED. [7] Men in this population who take glycine may experience a modest incremental reduction in postprandial glucose. This is unlikely to cause harm and may even be mildly beneficial, but it adds a variable that clinicians managing tight glycemic control should know about.

Pharmacodynamic Concern 3: CNS Inhibitory Activity

Glycine's role as an inhibitory neurotransmitter is primarily spinal and brainstem, not cerebral. At supplemental doses of 3 to 5 g, sedative effects are not strongly documented. Because alprostadil has no meaningful CNS activity, this overlap is theoretical rather than clinically demonstrated.

HealthRX Interaction Classification Framework for Alprostadil + Glycine

| Interaction Domain | Evidence Level | Clinical Significance | Action Required | |---|---|---|---| | Pharmacokinetic (CYP/transporter) | No evidence | None | None | | Vasodilation / Blood pressure | Animal + mechanistic | Low to moderate | Monitor BP; avoid high-dose glycine within 60 min of alprostadil use | | Glycemic axis | Human RCT (modest) | Low (relevant in diabetics) | Note in diabetic patients; monitor glucose | | CNS inhibition | Theoretical | Negligible | No action needed | | Collagen/vascular remodeling | Preclinical only | Potentially beneficial | No restriction |

Dose-Separation Windows: Do They Apply Here?

Dose separation is most relevant when two substances share the same elimination pathway or compete for the same receptor. Given that no pharmacokinetic interaction exists between glycine and alprostadil, rigid separation windows are not scientifically required.

Practical Timing Advice

A sensible precaution for men who are sensitive to blood pressure changes is to avoid taking a glycine dose in the immediate 60-minute window around alprostadil administration. The pharmacokinetics of intracavernosal alprostadil show that systemic levels return to baseline within 60 minutes. [2] Glycine taken as a 3 g evening sleep dose and alprostadil used as an on-demand injection are unlikely to overlap in clinical practice, because the onset and offset of each are well within a two-hour window.

For men using MUSE (intraurethral suppository), the systemic absorption is slightly higher than with Caverject but still low. The same 60-minute advisory applies as a conservative buffer.

When Separation Is Not Practical

Some men take daily glycine for joint health or collagen synthesis, not just at bedtime. A 5 g daily collagen-plus-glycine powder taken in the morning does not pose measurable risk alongside an on-demand alprostadil dose used hours later. The half-life of glycine after a 3 to 5 g oral dose is approximately 45 to 60 minutes for the first-pass metabolic phase. By four hours post-dose, plasma glycine is near baseline.

Monitoring: What to Watch For

Blood Pressure

Men using alprostadil should already be monitoring blood pressure periodically, per the Caverject prescribing information's standard precautions. [1] Adding glycine does not require new monitoring equipment or new laboratory tests. If a man reports new lightheadedness after starting glycine alongside alprostadil, checking a seated and standing blood pressure is a reasonable first step.

The American Heart Association recommends home blood pressure monitoring for men with cardiovascular risk factors using vasoactive medications. Hypertension guidelines from the AHA/ACC (2017) define a threshold of concern at systolic readings below 90 mmHg. [8] If readings consistently fall below that threshold, dose adjustment or discontinuation of glycine may be warranted.

Blood Glucose in Diabetic Patients

For men with type-2 diabetes or impaired fasting glucose, glycine's GLP-1-stimulating effect is modest but real. [4] Adding 3 to 5 g of glycine daily may improve postprandial glucose control slightly, which is not inherently a problem. The clinical issue arises if a diabetic man is on sulfonylureas or insulin and glycine pushes glucose lower than anticipated. A fasting glucose check at four weeks after starting glycine is a reasonable precaution in this subgroup.

No Required Lab Panel

Unlike many supplement-drug pairs (fish oil plus warfarin, for example, which can alter INR), glycine with alprostadil does not require a dedicated laboratory panel. Routine monitoring that is already indicated for alprostadil users, specifically cardiovascular assessment and glycemic control in diabetics, is sufficient.

What the Guidelines Say About Alprostadil Drug Interactions

The FDA label for Caverject lists sympathomimetics, antihypertensives, and other vasoactive drugs as substances warranting caution due to additive hemodynamic effects. [1] Glycine is not listed. The American Urological Association (AUA) guidelines on ED treatment, last substantially updated in 2018 and reaffirmed subsequently, do not address glycine by name. The AUA ED guideline advises clinicians to review all concurrent medications and supplements before prescribing intracavernosal agents, specifically because of cumulative hypotension risk.

The Endocrine Society's clinical practice guideline on male hypogonadism does not specifically address alprostadil-supplement co-administration but notes that vasoactive agents in general should be used with caution in men with autonomic dysfunction or significant cardiovascular disease. [9]

"Patients using intracavernosal vasoactive agents should be counseled to disclose all prescription, over-the-counter, and dietary supplement use, as additive hemodynamic effects can occur with agents not traditionally classified as antihypertensives," according to the Caverject prescribing information's precautions section. [1]

Special Populations: Who Needs Extra Caution?

Men with Cardiovascular Disease

Coronary artery disease, peripheral arterial disease, or a recent cardiac event increases the importance of hemodynamic stability. For these men, the glycine-alprostadil vasodilation concern, though modest, carries more weight. A cardiologist or internist should be informed before starting any new supplement.

Men with Autonomic Neuropathy

Diabetic autonomic neuropathy impairs normal baroreflex compensation for blood pressure drops. These men are already at elevated risk for alprostadil-related hypotension. Adding glycine's mild vasodilatory signal, even if small, warrants more cautious monitoring.

Men on Multiple Antihypertensive Agents

A man already taking an ACE inhibitor, calcium channel blocker, and alpha-1 blocker who also uses alprostadil faces a meaningful background risk of cumulative hypotension. Glycine in this setting should be introduced gradually, starting at 1 to 2 g per day, with blood pressure checks at two-week intervals.

Men Taking Collagen Peptide Supplements

Many collagen peptide powders contain 2 to 3 g of glycine per serving as a structural component of hydroxyproline-rich peptides. Men who do not realize they are already consuming glycine as part of a collagen supplement should be asked about this specifically. The aggregate glycine dose from collagen plus standalone glycine powder could reach 6 to 8 g per day.

Is There Any Evidence That Glycine Could Help Erectile Function Directly?

No well-powered human RCT has tested glycine as a standalone treatment for erectile dysfunction. Mechanistically, glycine contributes to nitric oxide (NO) synthesis as a substrate (via the arginine-glycine-amidinotransferase pathway leading to creatine production, which spares arginine for NO production). This is an indirect, multi-step pathway with modest quantitative impact. A 2015 paper in Nitric Oxide explored glycine-mediated endothelial protection without making direct ED efficacy claims. [10]

Glycine is not a substitute for alprostadil. Men should not reduce their prescribed alprostadil dose based on a perceived synergistic benefit with glycine, as no dose-reduction trials exist.

Practical Summary for Patients and Clinicians

For Patients

Taking 3 to 5 g of glycine for sleep or joint support while using alprostadil as prescribed is likely safe for most men. Sit up slowly for a few minutes after an alprostadil injection or MUSE application. If you feel lightheaded, sit or lie down immediately. Tell your prescriber you are taking glycine, especially if you have diabetes, cardiovascular disease, or take antihypertensive medications.

For Clinicians

No dose adjustment to alprostadil is indicated based on concurrent glycine use. In diabetic patients, document glycine use alongside other supplements and recheck fasting glucose at the next visit. In men with autonomic neuropathy or multiple antihypertensives, a staged glycine introduction (starting at 1 g daily) minimizes the small additive hypotension risk. Annual review of all supplements during an ED follow-up visit is consistent with AUA best practice principles for vasoactive drug management.